Consequently, Roche has continued to develop new treatments to improve upon rituximab for these patient populations. The superior effects of obinutuzumab seen in the laboratory have been confirmed ...

Time to next anti-lymphoma treatment (TTNT) was also extended by 32% in patients receiving obinutuzumab plus chemotherapy compared to rituximab plus chemotherapy. Whilst there were no new adverse ...